INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE);CANCER RESEARCH TECHNOLOGY LIMITED
发明人:
Caroline Joy Springer,Dan Niculescu-Duvaz,Ion Niculescu-Duvaz,Richard Marais,Bartholomeus Marinus Josephus Marie Suijkerbuijk,Alfonso Zambon,Arnaud Nourry,Delphine Menard
申请号：
US14853199
公开号：
US09540372B2
申请日:
2015.09.14
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g.,B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.
